Affecting approximately 50% of patients with diabetes, DN is predominantly characterized by distal symmetric polyneuropathy, leading to sensory loss, pain, and motor dysfunction, often resulting in diabetic foot ulcers and lower-limb amputations
Potential Risks Adverse reaction Some adverse reactions may occur during the use of this injection, such as reactions at the injection site (irritation, erythema, induration, pain, itching, etc.), systemic reactions (headache, diarrhea, vasodilation, nausea, abdominal pain, etc.), water retention, nerve compression pain (such as wrist pain), etc.People with a BMI over 30 May have some underlying diseases or a decline in physical functions, and these adverse reactions may have a greater impact on them
Compound identity at a glance Name: Retatrutide INN: LY3437943 Class: Triple incretin receptor agonist Structure: 39-amino-acid synthetic peptide Dosing interval: Once weekly (research protocols) Developer: Eli Lilly For the full molecular reference (molecular formula, molecular weight, CAS number and the 39-amino-acid sequence) see the Retatrutide molecular profile
Molecular characterisation of small molecule agonists effect on the human glucagon like peptide-1 receptor internalisation
Continuous administration of natural GLP-1 increases insulin levels and results in lower blood glucose and hemoglobin A1C (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) (20)
